Galmed Pharmaceuticals Overview
Valuation check: GLMD's ROE is -89.05%, below the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow-89.05%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Galmed Pharmaceuticals (GLMD) currently reports a ROE of -89.05%. That is below the Healthcare sector average of 11.15%. Use the charts on this page to explore Galmed Pharmaceuticals's ROE history and peer comparisons.
Galmed Pharmaceuticals's ROE of -89.05% is lower than the Healthcare sector average of 11.15%. That is roughly 898.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Galmed Pharmaceuticals's current -89.05% should be judged against Healthcare norms (sector average: 11.15%) and against GLMD's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -89.05%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Galmed Pharmaceuticals, and consider following GLMD for alerts when major investors trade the stock.
Galmed Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows -89.05% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GLMD with unrelated industries.
